Introduction
Virus-mediated gene therapy has been proposed for many years and remains a promising approach supported by numerous experimental reports and a number of clinical trials. Among the currently used virus vectors, herpes simplex virus type-1 (HSV-1) possesses some unique characteristics that render it an attractive candidate. These include its high infectivity, the large capacity for accommodating multiple transgenes, the wide host range and the availability of antiherpetic agents that can abrogate an infection. Genetically engineered HSV-1 for cancer gene therapy includes replication-defective 1,2 and replication-competent HSV-1 vectors. [3] [4] [5] [6] Both types of viral vectors need to target specific tissues to avoid deleterious effects in normal tissues. For this purpose, tissue-or tumor-specific promoters have been proposed to control the expression of transgene or essential viral gene(s). 4, 7, 8 However, an influence of infected cell proteins (ICPs), encoded by the viral genes, on the expression of transgene was recently noticed. 9 HSV viral proteins are divided into three major kinetic classes on the basis of requirements for their expression and the times of their maximum rates of synthesis: immediate early (IE), early and late. 10 IE genes encode the major HSV regulatory proteins, and are transcriptionally activated by VP16, one of the tegument proteins carried by virions. 11, 12 The IE genes encode ICPs 0, 4, 22, 27 and 47. 10, 13, 14 All IE proteins except ICP47 are nuclear phosphoproteins 15 and act to regulate their own synthesis as well as the synthesis of proteins of later kinetic classes. [16] [17] [18] [19] [20] [21] [22] Since the genes of HSV are standard polymerase II transcription units, 23 exogenous polymerase II promoters used to express transgenes may be affected by HSV IE gene products in the same way as viral promoters are. If the expression of a transgene could be augmented by viral IE proteins, the specificity of tissue-or tumor-targeted therapy might thus be jeopardized. In the present study, we examined the effects of HSV-1 infection on the activity of several cellular promoters using luciferase as a reporter gene, and evaluated the effects of virus-borne individual HSV IE proteins on the expression of transgenes. We also studied the influence of HSV-1 infection on endogenous telomerase expression to explore the potential impact of virus infection in nontumor cells.
Results
Effect of superinfection with HSV-1 on tyrosinase promoter activity in B16 and H460 cells As a model promoter system, we used the tyrosinase promoter to elucidate the effect of superinfection with HSV-1 on promoter activity. Since tyrosinase is a pigmented cell-specific gene that is highly expressed in melanoma cells, 7 we first transfected B16 melanoma (pigmented) and H460 lung carcinoma (nonpigmented) cells with both Tyrosinase-2 and pLacZ plasmids. The former plasmid contains a tyrosinase promoter/luciferase reporter and the latter a cytomegalovirus (CMV) promoter/lacZ reporter. At 24 h after transfection, cells were superinfected with ICP27(À) mutant 5dl 1.2, a replication defective HSV-1 mutant, at multiplicity of infection (MOI) of B5 or mock infected. At 48 h after transfection, cells were collected for luciferase and bgalactosidase enzyme assays. The tyrosinase promoter activity was expressed as the ratio of luciferase to bgalactosidase activity (the relative luciferase activity) to normalize the variation in transfection efficiency. The relative luciferase activity in B16 cells was near 29-fold higher than that in H460 (3.5070.14 Â 10 6 versus 1.2270.51 Â 10 5 , respectively; Po0.00002). Superinfection with 5dl 1.2 significantly increased luciferase activity in H460 cells by 15-fold (Po0.00003), but had no effect in B16 cells (P¼0.44). Consequently, the relative luciferase activity in B16 cells became only 1.5-fold of that in H460 cells ( Figure 1A ). Thus, superinfection with the HSV-1 virus completely abolished the cell-type specificity of the tyrosinase promoter.
Effects of superinfection with HSV-1 on prostatespecific probasin promoter in LNCaP and HeLa cells
We next studied the prostate-specific probasin promoter activity in prostate cancer LNCaP and cervical cancer HeLa cell lines. Plasmids pABB, containing the probasin promoter linked to the luciferase reporter gene, and pLacZ were co transfected into LNCaP and HeLa cells. Cells were then superinfected with 5dl 1.2 or mock infected as above, and collected after 24 h for luciferase and b-galactosidase assays. Again, relative luciferase activity was calculated to measure the activity of the probasin promoter. Without superinfection, the relative luciferase activity in LNCaP cells was only marginally higher than that in HeLa cells (5.7270.34 Â 10 3 versus 4.0670.04 Â 10 3 , respectively; P¼0.008). This was because the activity of the probasin promoter in LNCaP cells is greatly dependent on the presence of androgen analogues, such as R1881, 24 which were not added in the present study to avoid possible interference. Superinfection with 5dl 1.2 significantly increased the relative luciferase activities for both cell lines, especially HeLa cells, where the relative luciferase activity was paradoxically 3.3-fold higher than that in LNCaP cells 
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Effects of superinfection with HSV-1 on telomerase promoter activity in tumor and non-tumor cells
We further tested if upregulation of promoter activity by HSV-1 infection also occurs in nontumor cells. Upregulation of human telomerase reverse transcriptase (hTERT) has been shown to play a critical role in carcinogenesis 25, 26 and both the hTERT gene and its promoter have higher levels of activity specifically in tumor cells. 27, 28 All of these features render the hTERT promoter an attractive target for cancer gene therapy. We thus examined if superinfection with HSV-1 vector would alter the activity of this promoter. We transfected plasmid pTLuc into lung carcinoma H460, mouse melanoma B16 and adult normal human lung fibroblast (NHLF) cells. Cells were then infected with 5dl 1. , and 3.170.5 Â 10 3 , for H460, B16 and NHLF, respectively), superinfection with 5dl 1.2 markedly increased the luciferase activity in H460, B16 cells and NHLF by 8377%, 31075% and 68724%, respectively ( Figure 2 ) (Po0.01 for all the cases).
Infection with HSV-1 mutant upregulated the endogenous telomerase activity in non-tumor cells
We further examined if the HSV-1-infection-induced upregulation of hTERT promoter activity would alter the endogenous telomerase activity in nontumor cells. NHLF and HUVEC were infected with either 5dl 1.2 at an MOI of B2 or mock infected. The relatively lower titer we used here was because of overt cytopathic effect of 5dl 1.2 in HUVEC at an MOI of 5. After 24 h, cells were collected for quantitation of telomerase activity. By using Polymerase Chain Reaction-based Enzyme Immunoassay (PCR-EIA), 29 the telomerase activity was expressed as the absorbance at 450 nm. In both NHLF and HUVEC, infection with 5dl 1.2 significantly increased the absorbance by four-and eight-fold, respectively (P¼0.005 and 0.004, respectively) ( Figure 3 ). Interestingly, infection with the ICP0(À) HSV-1 mutant 7134 did not significantly alter telomerase activity in either NHLF or HUVEC compared with that in mock-infected samples (P¼0.051 or 0.106, respectively), suggesting that ICP0 may be responsible for the observed promoter upregulation.
Effects of superinfection with HSV-1 deletion mutants on promoter activity
To further explore which HSV-1 gene(s) plays the major role in altering cellular promoter activity, the tyrosinase promoter-luciferase reporter construct was transfected into H460 cells followed by superinfection with various HSV-1 mutants or mock infection ( Figure 4a ). Infection with wild type strain KOS, ICP22(À) mutant d22LacZ, ICP27(À) mutant 5dl 1.2 and ICP34.5/ICP6 double deletion mutant G207 6 significantly increased the luciferase activity by 505743% (Po0.002), 497714% (Po0.0003), 991769% (Po0.00001), and 525786% (Po0.0005), respectively, relative to mock-infected control cell cultures. Infection with ICP4À mutant CgalD3 or TOZ.1, 30 a mutant with multiple deletions for ICP4, ICP22, ICP27, and UL41, slightly upregulated the tyrosinase promoter activity by 6973% (Po0.03) and 57717% (Po0.03), respectively. The increases in promoter activity were significantly less than that with the previous mutants (Po0.04). Interestingly, a VP16(À) mutant V422 and an ICP0(À) mutant 7134 did not significantly alter the promoter activity (P¼0.67 and 0.08, respectively). Figure 4b demonstrated the mRNA levels of ICP0 in cells infected with the above viruses using quantitative RT-PCR. While the transcription levels of all mutant HSV-1 strains were much lower than wild-type KOS strain, V422, 7134, CgalD3 and TOZ.1 expressed much less ICP0 than the others. Therefore, the ICP0 mRNA level was positively correlated with the upregulated tyrosinase promoter activity (Fig.4a ). It appears that expression of other IE gene products such as ICP4, ICP22 and ICP27 increases the mRNA levels of ICP0 in the order of significance of ICP44 ICP22¼ICP27. ICP6 and ICP34.5 double deletion also significantly reduces ICP0 message level but not as remarkable as ICP4 deletion.
Effects of VP16, ICP4 or ICP0 on activity of the tyrosinase promoter in H460 cells
To verify whether VP16, ICP4 and/or ICP0 are capable of enhancing the activity of exogenous promoters in human Results from PCR-EIA for quantitation of telomerase activity were expressed as absorbance unit. Data were derived from the mean of two determinations 7SE.
HSV-1 upregulates telomerase C-T Yang et al cells, we cotransfected plasmid Tyrosinase-2 with pRG50 (expressing VP16), pDS-16 (expressing ICP0), pLK (expressing ICP4) or pLacZ (control plasmid) into H460 human carcinoma cells, and examined the effects of expression of the each viral gene on tyrosinase promoter activity. After 48 h, cells were lysed for luciferase activity assay. Luciferase activity driven by the tyrosinase promoter was 6.6-fold higher in cells cotransfected with pDS-16 than in those cotransfected with control plasmid pLacZ (P¼0.02). In contrast, cotransfection with pRG50 or pLK had no significant effect in luciferase activity compared to the control plasmid (P40.5 in either comparison, Figure 5 ).
Discussion
Virus-mediated gene therapy takes advantage of the high efficiency with which viral vectors are able to introduce foreign genes into mammalian cells. Deregulation of cellular promoters caused by infection with viral vectors undoubtedly leads to a safety concern for virus-mediated gene therapy. Our results suggest that transgene expression mediated by plasmid constructs, such as amplicons that are widely used in HSV-1-mediated gene transfer, 31, 32 will likely be inappropriately turned on by the coexisting helper virus. Recently, it has been reported that HSV-1 IE proteins abrogated the tetracycline regulated transgene expression in an amplicon system, 33 demonstrating a similar interference of viral IE proteins on transgene expression. The disregulation of activity of cellular promoters by HSV-1-infection may not be restricted to transiently transfected genes, as expression of many endogenous genes can also be affected in HSV-1 infected cells. 34 Our present study shows that HSV-1 infection deregulated the activity of hTERT promoter present in cells in both episomal and in the genome. In addition, we also showed that HSV-1 infection can also upregulate the expression of hTERT in nontumor cells, which may cause further safety concern since upregulation of telomerase has been shown to play a critical role in carcinogenesis. 25, 26 Alteration of telomerase activity has been reported in cells infected with HIV and Kaposi's sarcoma-associated herpesvirus. [35] [36] [37] While HSV-1/2 are not considered carcinogenic, clinical correlation between HSV-2 and human carcinoma of cervix remains to be a debatable issue. [38] [39] [40] [41] [42] [43] [44] [45] [46] It is unclear whether the HSV-1-induced upregulation of telomerase activity showed in the present study could afford individual cell freedom from senescence, allow accumulations of the genetic changes and chromosome instability, and eventually lead to pathological state such as cancer. Our results also showed that the upregulation of the endogenous telomerase was independent of viral replication but rather dependent on certain viral IE gene expression. As most HSV-1 vectors currently used for tumor gene 
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therapy including the oncolytic vectors that are currently on clinical trials 47, 48 express ICP0 and ICP4 genes, the potential risk of deregulation of gene expression in infected normal cells should be considered. In the case of oncolytic HSV-1 vectors, the risk of adverse deregulation in host cells may not pose a significant problem since the duration of the viral IE gene expression is short. In tissues where HSV-1 virus infection is persistent or frequently recurrent, the impact of the virus-induced deregulation of cellular gene expression must be seriously investigated.
Our results further suggest that the deregulation of cellular promoter and upregulation of host telomerase activity may be attributed to the HSV-1 IE genes products, especially ICP0, in agreement with previous studies on the effects of this viral protein on cellular gene expression. [49] [50] [51] [52] Although the exact mechanism by which ICP0 causes this enhancement is not yet clear, it has recently been reported that ICP0 may interact with the cellular transcription factor BMAL1, a member of the basic helix-loop-helix PER-ARNT-SIM superfamily of transcriptional regulators. 53 Despite not being essential for viral replication, lacking ICP0 gene significantly hampers the viral replication in cultured cells, especially infected with low MOIs. 54, 55 ICP0 is a potent transactivator of all three kinetic classes of HSV promoters, 56, 57 and its transactivating activity has been shown to increase synergistically in the presence of ICP4, [19] [20] [21] [22] 58, 59 which may explain the fact that the ICP0+/ICP4À mutant (such as CgalD3 and TOZ.1) had a markedly lower magnitude of enhancement in tyrosinase promoter activity than the wild-type or other ICP0+/ICP4+ mutants (Fig.4a) . Similarly, since VP16 can activate the transcription of all IE genes 60,61 deletion of the VP16 gene could significantly abolish HSVinduced increase in the activity of cellular promoters as shown by infection with the VP16(À) mutant V422. In addition, the above mutants also showed significantly lower levels of ICP0 comparing to ICP0+/ICP4+ mutants (Fig.4b) , which further emphasizes the role of ICP0 in regulating cellular promoter activity. On the other hand, ICP0 may enhance certain cellular gene expression but inhibits the others as shown by recent studies using cDNA arrays on infected cells 34, 62, 63 It is interesting to note that ICP27-mutant 5d1.2 showed significantly higher level of tyrosinase promoter activity than the wild-type KOS, which suggest that ICP27 may repress the ICP0 caused effect.
HSV-1 vectors are powerful tools for gene transfer and have been widely used in gene therapy in experimental animal models 6 and some oncolytic herpes mutants have been in clinical trials for cancer therapy. 48, 64, 65 While the safety concern for viral vectors has been concentrated to virus-induced lytic toxicity. 48, [66] [67] [68] our present study alerts to the potential risk of oncogenesis through deregulation of host gene expression in normal cells. It is not unreasonable to predict that nonherpes viral vectors may have similar effects on host cells. For HSV-1, it seems safer to use vectors with multiple deletions of all IE genes 69, 70 or virus-free amplicons [71] [72] [73] [74] for gene transfer to nontumoral tissues. For oncolytic viral vectors, it might be plausible to put the IE genes, particularly the ICP0 and 4, under strict cell-type specific control to reduce their expression in normal cells. 76 Adult normal human lung fibroblasts (NHLF) and the specific growth medium (Fibroblast Growth Medium-2 BulletKit) were purchased from Clonetics (BioWhittaker, Inc., Walkersville, MD, USA). Normal endothelial cells (HUVEC) were isolated from human umbilical cord veins as described previously. 77 Cells were cultured in medium MCDB 107 (JRH Biosciences, Lenexa, KS, USA) supplemented with 2% FCS and a fibroblast growth factor-enriched fraction of porcine brain extract (1 mg/ml).
Plasmids
Plasmid pLacZ contains the cytomegalovirus (CMV) promoter-regulated LacZ gene 78 Plasmid pTLuc was generated by subcloning a 342 bp fragment of the hTERT promoter (À344 to À2 relative to the hTERT ATG) from plasmid P-344 79 upstream of the luciferase reporter gene in the pGL2-Basic vector (pGL2, Promega, Madison, WI, USA). Plasmid Tyrosinase-2, containing the tyrosinase promoter-regulated luciferase gene, 7 was kindly provided by Dr. David L. Bartlett (National Cancer Institute, Frederick, MD, USA). Plasmid pAAB was derived from pGL2, containing a probasin promoter (À426/+28) upstream of the luciferase gene. 80 Plasmid pDS-16 contains a full-length cDNA of ICP0 gene 13 controlled by its own promoter, and was kindly provided by Dr S Silverstein (Columbia University); pRG50 expresses VP16 under the cytomegalovirus (CMV) promoter and was a gift from Dr P O'Hare (Marie Curie Research Institute, UK).
Viruses
The wild-type KOS strain HSV-1 (KOS) was purchased from ATCC. The VP16-defective HSV-1 mutant V422 81 was kindly given by Dr J Smiley (University of Alberta, Alberta, Canada). The HSV-1 mutant d22LacZ, defective in ICP22 82 was a gift from Dr Stephen A Rice (University of Minnesota Medical School). Mutants 7134 and 5dl 1.2, defective in ICP0 83 and ICP27 84 respectively, were provided by Dr Priscilla A Schaffer (University of Pennsylvania School of Medicine). The ICP4 deletion mutant, CgalD3 85 was a gift from Dr Paul Johnson (Neurovir Inc., Vancouver, BC, Canada). G207, a derivative of wild-type HSV-1 strain F in which both copies of ICP 34.5 gene are deleted and a lacZ disruption disables the ICP6 gene, was provided by Neurovir Inc. The HSV-1 mutant TOZ.1, which is deleted of the genes ICP4, ICP22, HSV-1 upregulates telomerase C-T Yang et al ICP27 and UL41, was a kind gift from Dr William Goins (University of Pittsburgh). All viruses were propagated and titered on cultured 7B cell except 7134 and V422, which were titered on the U 2 OS cell.
Transfection and Superinfection
Cells were seeded in six-well plates 12 h before transfection. Monolayers at 40-60% confluency were washed once with PBS followed by addition of 0.8 ml of serumfree medium for each well and put back into the CO 2 incubator for 30 min before transfection. In all, 2 mg of total plasmid(s) for each well were used for transfection using Lipofectamine PLUS (Life Technologies, Grand Island, NY, USA) according to the manufacturer's instruction. At 24 h after transfection, cells were either infected (superinfection) with various HSV-1 mutants at an MOI of 5 or mock infected with virus-free medium. After incubation at 371C for 24 h, cell lysates were collected for luciferase and/or b-galactosidase enzyme assays.
Luciferase enzyme assay
After removal of growth medium, 250 ml of 1 Â Reporter Lysis Buffer (RLB, Luciferase Assay System, Promega, Madison, WI, USA) was applied to the cultured cells in each well of 6-well plates followed by a 15-min incubation at room temperature. Cell lysates were prepared by scraping cells in the presence of 1 Â RLB, and then transferring them into 1.5 ml microfuge tubes. Cell debris was removed by centrifuge at 12 000 g for 2 min at room temperature. A volume of 20 ml of lysates from NHLF samples or 10 mL of lysates from other cell samples was mixed with 100 ml of Luciferase Assay Reagent (Luciferase Assay System; Promega) and the light intensity was measured for 30 s in a luminometer (OPTOCOMP I, MGM Instruments, Inc., Hamden, CT, USA).
b-Galactosidase enzyme assay
A measure of 50 ml of cell lysate in 1 Â RLB was mixed with equal volume of Assay 2 Â Buffer (b-Galactosidase Enzyme Assay System, Promega) in each well of a 96-well plate and was incubated at 371C for 30 min before the reaction was stopped by adding 150 ml of 1 M sodium carbonate in each well. The absorbance of samples at 420 nm was read in a plate spectrophotometer (mQuant, BIO-TEK Instruments, Inc., Winooski, VT, USA).
Single-step growth assay
NHLF cells were seeded in six-well plates at a density of 6 Â 10 5 cells/well and infected 12 h later with either a209 amplicon CgalD3/mixture or CgalD3 only at an MOI of 1. The infected cells were then harvested at 48 h by cell scraping and collection of the media. Samples were then frozen/thawed and titered by plaque assay on 7B cell monolayers.
(PCR-EIA) for quantitation of telomerase activity
For the preparation of cell extracts, cells tested were suspended at lysis buffer (10 mM Tris-HCl, pH 7.5, 1 mM MgCl 2 , 1 mM ethyleneglycol bis(2-aminoethyl-ether) tetraacetic acid (EGTA), 0.5% 3-[3-cholamidopropyl] dimethylammonio)-1-propane sulfonate (CHAPS), 10% glycerol, 5 mM mercaptoethanol and 0.1 mM phenylmethanesulfonyl fluoride) and incubated on ice for 30 min. The sequence and source of TS and CX primers were previously described. 29 Biotinylated TS (TS-B) and digoxigeninated CX (CX-D) oligonucleotides were purchased from Genasia Scientifics Inc., Taipei, Taiwan. The PCR-EIA method was performed as follows. First, the TS-B and CX-D primers were heated at 951C for 5 min before being added to the reaction mixtures. Then, aliquots of cell extracts containing 3 mg protein were added to 30 ml reaction mixtures containing 0.5 mM TS-B primer, 0.5 mM CX-D primer, 2 U of Taq DNA polymerase (HT Biotech. Ltd, Taipei, Taiwan), 20 mM Tris-HCl pH 8.3, 1.5 mM MgCl 2 , 63 mM KCl, 0.005% Tween-20, 1 mM EGTA, 50 mM dNTP and 0.1 mg/ml bovine serum albumin. RNase digestion was performed as a control to confirm that the activity was that of telomerase. For these reactions, cell extracts were preincubated with 200 mg/mL of RNase A (Boehringer Mannheim, Mannheim, Germany) at room temperature for 20 min before being added to the reaction mixtures. The TRAP (Telomeric Repeat Amplification Protocol) 86 reaction mixtures were incubated at 251C for 15 min, and then amplified by 30 cycles of PCR at 941C for 30 s, 551C for 30 s, and 721C for 1 min in a DNA Thermal Cycler (Perkin-Elmer Cetus, Norwalk, CT, USA). After PCR, 5 ml of the PCR products was dispensed into streptavidincoated wells (Boehringer Mannheim), and incubated with 100 ml of anti-digoxigenin antibody conjugated with horseradish peroxidase (15 mU/mL, Boehringer Mannheim) at 301C for 60 min in EIA reaction buffer, which contained 100 mM Tris, pH 7.4, 150 mM NaCl, 0.1% bovine serum albumin, 5% fetal bovine serum, 0.1% Tween-20, 0.1% Nonidet P-40 and antibiotics (100 U/ml penicillin, 100 U/ml streptomycin, 0.25 mg/ml amphotericin B). The plates were washed four times with 200 ml of washing solution (100 mM Tris , pH 7.4, 150 mM NaCl, 0.1% Tween-20, 0.1% Nonidet P-40), and enzyme reactions were stopped by the addition of 100 ml of 2 N HCl to each well. Colorimetric signals were determined by measuring the absorbance at 450 nm using an automatic microwell reader (ThermoMax, Molecular Devices Co., Sunnyvale, CA, USA).
Quantitative RT-PCR
Total RNA was extracted from infected cells with TRIzol Reagents (Invitrogen). Random hexamers were used for cDNA synthesis with TaqMan Reverse Trascription Reagents (Applied Biosystems). For quantitative PCR (QPCR), primers ACT-F (ACGAGGCCCAGAGCAA GAG) and ACT-R (TCTCCATGTCGTCCCAGTTG) were used to detect b-actin cDNA as internal control. Primers ICP0-F (TTACGTGAACAAGACTATCACGGG) and ICP0-R (TCCATGTCCAGGATGGGC) were used to detect ICP0 cDNA (the amplicon size was 51 bp). The QPCR was achieved by using SYBR Green Master Mix (Applied Biosystems) with ABI PRISM 7000 (Applied Biosystems).
Statistical method
All experiments were conducted in triplicate unless specified. Results are expressed as means 7SE. Statistical comparisons were made by two-tailed t-test. A value of P less than 0.05 was accepted as significant.
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